Is Nektar Therapeutics (NKTR) a Buy, Sell, or Hold?
Nektar Therapeutics
NASDAQ:NKTR
$67.17 USD
-$1.15 (-1.68%)
- Volume
- 814.75K
- Average Volume
- 1.17M
- Market Capitalization
- $1.31B
- P/E Ratio
- -7.98
- Dividend Yield
- 0.00%
- Price Target
- $151.00
- Year High
- $109.00
- Year Low
- $21.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Howard W. Robin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NKTR |
| CUSIP | 640268306 |
| CIK | 0000906709 |
| Web | https://www.nektar.com |
| Phone | 415 482 5300 |
| Currency | USD |
| Employees | 63 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.25 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.21 |
| Quick Ratio | 10.21 |
| Cash Ratio | 2.29 |
Sales & Book Value
| Annual Sales | $55.23M |
| Price / Sales | 23.59 |
| Cash Flow | -8.24 |
| Price / Cash Flow | -6.44 |
| Price / Book | 2.88 |
Price Target and Rating
| Average Stock Price Forecast | $151.00 |
| High Stock Price Forecast | $192.00 |
| Low Stock Price Forecast | $80.00 |
| Forecast Upside/Downside | -55.52% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 33 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-9.73 |
| Trailing P/E Ratio | -7.98 |
| PEG Ratio | 6.50 |
| P/E Growth | 6.50 |
| Net Income | $-164.08M |
| Net Margin | -284.18% |
| Pretax Margin | -284.41% |
| Return on Equity | -87.00% |
| Return on Assets | -20.71% |
Financials Score
| AltmanZ Score | -2.34 |
| Piotroski Score | 1.00 |
| Working Capital | 531.33M |
| Total Assets | 763.27M |
| Ebit | -126.69M |
| Market Cap | 1.34B |
| Total Liabilities | 187.06M |
Poll Results
About Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for ... systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-26 16:30:00
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
2026-06-24 15:39:19
Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted average price of $60.75 per share. This sale represented 26.64% of his direct common stock holdings and reduced his direct position from 75,073 to 55,045 shares.
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
2026-06-23 07:55:41
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-03 16:15:00
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
2026-05-27 18:15:00
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m.
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
2026-05-16 10:09:15
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Nektar Therapeutics Q1 Earnings Call Highlights
2026-05-08 16:09:38
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial results and providing updates across its pipeline during its earnings call. Get Nektar Therapeutics alerts:Sign UpREZPEG positioned for phase III in atopic dermatitis President and CEO Howard Robin said the company is “exceptionally proud” of progress over the past year and highlighted phase IIb results in atopic dermatitis and alopecia areata that he said demonstrate clinically meaningful outcomes in two “distinct autoimmune and inflammatory disease settings.
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
2026-05-08 13:56:19
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Frequently Asked Questions
-
What is the current Nektar Therapeutics (NKTR) stock price?
-
Nektar Therapeutics(NASDAQ:NKTR) stock price is $67.17 in the last trading session. During the trading session, NKTR stock reached the peak price of $109 while $21.02 was the lowest point it dropped to. The percentage change in NKTR stock occurred in the recent session was --1.68% while the dollar amount for the price change in NKTR stock was -$-1.15.
-
NKTR's industry and sector of operation?
-
The NASDAQ listed NKTR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NKTR?
-
Jonathan Zalevsky | Senior Vice President and Chief Research & Development Officer
Howard W. Robin | Chief Executive Officer, President & Director
Ken Franke | Senior Vice President of Biologics Process Development & Manufacturing
Mary Tagliaferri | Chief Medical Officer
Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary -
How many employees does NKTR have?
-
Number of NKTR employees currently stands at 63. NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, US.
-
Link for NKTR official website?
-
Official Website of NKTR is: https://www.nektar.com
-
How do I contact NKTR?
-
NKTR could be contacted at phone #415 482 5300 and can also be accessed through its website. NKTR operates from 455 Mission Bay Boulevard South, San Francisco, CA 94158, US.
-
How many shares of NKTR are traded daily?
-
The average number of NKTR shares traded daily for last 3 months was 1.17M.
-
What is the market cap of NKTR currently?
-
The market value of NKTR currently stands at $1.31B with its latest stock price at $67.17